Global Genetically Engineered Universal Nuclease Market Growth 2025-2031

The global Genetically Engineered Universal Nuclease market size is predicted to grow from US$ 88 million in 2025 to US$ 186 million in 2031; it is expected to grow at a CAGR of 13.3% from 2025 to 2031.

Genetically engineered universal nucleases are a class of enzymes that can cut phosphodiester bonds in DNA or RNA molecules. The cutting of these enzymes does not depend on a specific nucleotide sequence, but can cut at any position of the molecular chain. It can degrade all forms of DNA and RNA, including single-stranded, double-stranded, linear, circular, natural and denatured nucleic acids. Genetically engineered universal nucleases do not recognize and bind to specific DNA sequences, but randomly cut the target molecules. This makes them important in applications that require extensive degradation or cutting of nucleic acid chains, such as genomics research, RNA degradation, sample preparation, and certain types of nucleic acid modification experiments.

United States market for Genetically Engineered Universal Nuclease is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Genetically Engineered Universal Nuclease is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Genetically Engineered Universal Nuclease is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Genetically Engineered Universal Nuclease players cover Thermo Fisher Scientific Inc., RayBiotech, TransGen Biotech, Yeasen, GenScript, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Genetically Engineered Universal Nuclease Industry Forecast” looks at past sales and reviews total world Genetically Engineered Universal Nuclease sales in 2024, providing a comprehensive analysis by region and market sector of projected Genetically Engineered Universal Nuclease sales for 2025 through 2031. With Genetically Engineered Universal Nuclease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Genetically Engineered Universal Nuclease industry.

This Insight Report provides a comprehensive analysis of the global Genetically Engineered Universal Nuclease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Genetically Engineered Universal Nuclease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Genetically Engineered Universal Nuclease market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Genetically Engineered Universal Nuclease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Genetically Engineered Universal Nuclease.

This report presents a comprehensive overview, market shares, and growth opportunities of Genetically Engineered Universal Nuclease market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Purity ＞ 95%
Purity ≤ 95%

Segmentation by Application:
Medical and Biological Laboratories
University Research Room
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific Inc.
RayBiotech
TransGen Biotech
Yeasen
GenScript
Beyotime
KACTUS
ACROBiosystems
Merck
ProSpec
Gproan
Bio-Techne Corporation
AMSBIO
Enzynomics
ProteoGenix
Vazyme
Sino Biological
Novoprotein
New England Biolabs

Key Questions Addressed in this Report

What is the 10-year outlook for the global Genetically Engineered Universal Nuclease market?

What factors are driving Genetically Engineered Universal Nuclease market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Genetically Engineered Universal Nuclease market opportunities vary by end market size?

How does Genetically Engineered Universal Nuclease break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.